EUCTR2005-004195-20-DK进行中（未招募）1 期
A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation. - ACT IV
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject or the subject’s legally authorized representative (parent or legal guardian) must comprehend and sign a written informed consent and at US sites, HIPAA Authorization; and at European sites, per EU Privacy Directive as implemented by member states in national law, as applicable;
- •2.Subject must be 18 years of age or older;
- •3.Subject who is female must be non-pregnant, non-nursing and if pre-menopausal, must be using an effective form of birth control from time of screening until 30-day follow-up. Methods of birth control considered to be effective would include hormonal contraception (the pill), an intrauterine device (IUD), condoms in combination with a spermicidal cream, total abstinence or sterilization;
- •4.Subject must have symptomatic AF that has been sustained for greater than 3 hours and less than or equal to 45 days. The presence of atrial arrhythmia will be documented by a 12-lead ECG recording at Screening. Atrial fibrillation is characterized by atrial activity which is either absent or chaotic both in amplitude and in rate;
- •5.Subject must have adequate anticoagulant therapy in the judgment of the Investigator. (If AF has lasted more than 48 hours then subjects should be managed in accordance with standard of practice as recommended by ACC/AHA/ESC practice guidelines) (Fuster V et al, 2001);
- •6.Subject must have systolic blood pressure (BP) above 90 mmHg and less than 160 mmHg and diastolic BP less than 95 mmHg at screening and baseline. (Note: Blood pressures will be measured 3 times within 5 minutes, after resting supine for 5 minutes and averaged to determine a baseline BP);
- •7.Subject must have a body weight between 45 and 136 kg (99 and 300 lbs).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Have known or suspected prolonged QT or uncorrected QT interval of >0.440sec as measured at Screening on a 12 lead ECG, familial long QT syndrome, or previous Torsades de Pointes;
- •2.Have symptomatic bradycardia or ventricular rate less than 50 bpm as documented by 12-lead ECG at Screening, unless controlled by a pacemaker;
- •3.Have a QRS interval > 0.14 sec unless subject has pacemaker at screening;
- •4.Have Class IV congestive heart failure (HF), HF requiring intravenous inotrope therapy, or be in cardiogenic or septic shock or other forms of shock requiring vasopressors or mechanical ventilation;
- •5.Have a Myocardial Infarction (MI), acute coronary syndrome, cardiac surgery (including PTCA or Stent placement), within 30 days prior to enrollment;
- •6.Have significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis;
- •7.Have failed electrical cardioversion;
- •8.Be concurrently participating in another drug study or have received an investigational drug within 30 days prior to enrollment, or have previously received RSD1235;
- •9.Have any known secondary causes of AF such as alcohol intoxication, pulmonary embolism, hyperthyroidism, acute pericarditis or hypoxemia (oxygen saturation less than 90% on room air);
- •10.Have serious pulmonary, hepatic, metabolic, renal, gastrointestinal, central nervous system or psychiatric disease, infection, febrile illness (oral temperature > 38.5°C), end stage disease states, or any other disease that could interfere with the conduct or validity of the study or compromise subject safety;
- •11.Have uncorrected electrolyte imbalance (serum potassium of less than 3.5 mmol/L must be corrected and documented 6 hours or less prior to enrollment);
- •12.Have clinical evidence of digoxin toxicity in the opinion of the Investigator;
- •13.Have received intravenous Class I or Class III antiarrhythmic drugs or IV amiodarone within 24 hours prior to the start of the first study drug infusion;
- •14.Be unable to communicate well with the Investigator and to comply with the requirements of the entire study;
- •15.Have any other surgical or medical condition that, in the judgment of the Investigator might warrant exclusion or be contraindicated for safety reasons;
- •16.Have previously been randomized to an RSD1235 study.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation. - ACT IVArrhythmias are abnormal rhythms of the heart. The term arrhythmia refers to a deviation from the normal sequence of initiation and conduction of electrical impulses, which cause the heart to beat. Arrhythmias may occur in the atria or the ventricles. Atrial arrhythmias are widespread and relatively benign.MedDRA version: 61Level: PTClassification code 10003658EUCTR2005-004195-20-SEAstellas Pharma US, Inc.240
进行中（未招募）
3 期
A study to assess the long-term safety of SAGE-718 in participants with Huntington’s diseaseISRCTN47421449Sage Therapeutics (United States)300
进行中（未招募）
1 期
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's DiseaseEUCTR2019-004368-22-ITBIOGEN IDEC RESEARCH LIMITED2,400
进行中（未招募）
1 期
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's DiseaseEUCTR2019-004368-22-GBBiogen Idec Research Limited2,400
进行中（未招募）
1 期
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302, and 221AD205MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersAlzheimer's DiseaseEUCTR2019-004368-22-DEBiogen Idec Research Limited2,400